Add as a preferred source on GoogleNurix Therapeutics Reports $4.73 Q3 GAAP EPS and $673.1M Revenue
Revenue rose 8,420.3% from a year earlier and exceeded estimates by $193.58 million. Cash, cash equivalents and marketable securities totaled $1.1 billion as of Aug. 31, 2026.
Nurix Therapeutics reported third-quarter GAAP earnings per share of $4.73 and revenue of $673.1 million, with both results exceeding market expectations for the period.
Earnings per share surpassed estimates by $1.64. Revenue increased 8,420.3% from a year earlier and came in $193.58 million above expectations.
Cash, cash equivalents and marketable securities totaled $1.1 billion as of Aug. 31, 2026, up from $592.9 million as of Nov. 30, 2025.
The report was published Oct. 12 at 4:08 p.m. ET (20:08 UTC).
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.